Can This Troubled Pharma Giant Bounce Back?

The patent expirations of key drugs have hit sales hard across the pharmaceutical industry, but few companies are facing as drastic a patent cliff as Eli Lilly (NYSE: LLY  ) over the rest of the decade. The company has managed to avoid the worst of the patent cliff so far, but concerns about what the future holds have taken their toll on this company's stock in 2013: Eli Lilly's shares are up only around 6% year-to-date, far underperforming many of big pharma's stronger stocks over the year's course so far.

What's dragging down investor optimism? Eli Lilly will lose patent protection for its top blockbuster, antidepressant Cymbalta, later this year in a move that could cost the company top dollar on its top line. A number of other patent losses on top-selling drugs have Eli Lilly scrambling to unlock its future sales blockbusters.

Eli Lilly hasn't performed up to many of its big pharma rivals' tracks so far this year, but is there an opportunity in this stock for investors? In the video below, Fool contributor Dan Carroll tells you what's ahead for Eli Lilly -- and the big threats facing this stock in the next few years to come.

Keeping an eye on Eli Lilly's future is the right move to make if you're looking at this stock. In fact, investing for the long term is the single best-proven and most reliable way to unlocking your portfolio's potential. Need help getting started? The Motley Fool's special free report "3 Stocks That Will Help You Retire Rich" names specific investment opportunities that could help you build long-term wealth and help you retire well. The Fool also outlines critical wealth-building strategies that every investor should know. Click here to keep reading.

Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2625479, ~/Articles/ArticleHandler.aspx, 9/26/2016 6:58:24 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 days ago Sponsored by:
DOW 18,261.45 -131.01 -0.71%
S&P 500 2,164.69 -12.49 -0.57%
NASD 5,305.75 -33.78 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/23/2016 4:01 PM
LLY $81.16 Down -0.13 -0.16%
Eli Lilly and Co. CAPS Rating: ***
^GSPC $2164.69 Down -12.49 -0.57%
S&P 500 INDEX CAPS Rating: No stars
TEVA $51.47 Up +0.24 +0.47%
Teva Pharmaceutica… CAPS Rating: ****